Competition among 277 biosimilars firms globally could crush prices
This article was originally published in Scrip
Executive Summary
International firms may be underestimating the level of potential competition in the global biosimilars market, which is likely to be highly fragmented with local producers playing a dominant role, according to senior executives of the biopharmaceutical services company, Quintiles.